BioNTech Recognizes Employees and Partners for Their Support in Developing Historic Vaccine

December 31, 2020

MAINZ, Germany, December 31, 2020 —BioNTech SE (Nasdaq: BNTX) today wants to express its thanks and gratitude not only to its employees but also to the many partners who have assisted the company in successfully developing a vaccine for COVID-19. BioNTech acknowledges that without the tireless effort from its' employees and partners, who have played a pivotal role in this effort, it would not have been able to achieve this historic company milestone, a journey which only began in early 2020. Data from its Phase 3 study have demonstrated that the vaccine is well-tolerated and 95% effective in preventing COVID-19. The vaccine has already received conditional marketing authorizations as well as emergency use authorizations in more than 45 countries around the world, including the United States and the European Union.

BioNTech's employees have made a significant contribution to this initiative, working around the clock to harness the power of mRNA and apply it to this effort of fighting against the devastating pandemic. In addition, our partner companies and organizations have provided the company with research expertise, critical supply support, and valuable insights and assistance throughout the development and trial process. Without them, achieving this result only 11 months after the initiation of Project Lightspeed would not have been possible.

"To address a global challenge like COVID-19, we have undertaken a worldwide effort to develop a well-tolerated and effective vaccine as quickly as science and cutting-edge technology will allow," said **Ugur Sahin, M.D., CEO and Co-founder of BioNTech**. "Despite the damage caused by the virus, I have been inspired each day by the spirit of collaboration and scientific discovery. It is one of the greatest honors of my life to be involved in this effort and to play a role in helping the world regain a sense of normality. I would like to thank each and every person that helped make this a reality."

BioNTech's management and employees appreciate the relentlessly support of many companies. A full list of BioNTech's partners supporting the COVID-19 project can be found below and at this link.

Our Partners:

A-C	D-L	M-P	Q-Z
A&C Biobuffer	D-HCC Dopamine Healthcare Communication	Maetrics	QIAGEN
Acuitas	Dätwyler Holding	MACHEREY-NAGEL	Ragon Institute of MGH, MIT and Harvard
Admedicum	Delpharm	Marble Pharma Consult	Ramsay Pharma
Agilent Technologies Sales & Services	Dermapharm	Medidata	RD-Biotech
Alexis Carpenter Consulting	DHL	medwiss-extern	Real Life Sciences
ALFA Chemicals	Discovery Life Sciences	Merck	Regeneron
Almac Clinical Services	Dr. Liebscher Consulting	Merck Chemicals	Rentschler
Applied Critical Fluids	Dunn Labortechnik	Meso Scale Diagnostics	Repligen Corporation
Aristo Group	Entourage Pharma Consulting	Miltenyi Biotec	Sartorius Lab Instruments
auceris	Eppendorf Vertrieb Deutschland	mpütranslations	Sartorius Stedim Biotech
Avanti Polar Lipids	Eurobio Scientific	Mundicare	Schott
Avia Pharma	Eurofins Genomics Germany	nerbe plus	Siegfried
Baxter	Evonik Industries	New England Biolabs	Siemens
Becton Dickinson	Finsbury Glover Hering Corporation	National Institutes of Health (NIH	Sigma-Aldrich Chemie
Bexon Clinical Consulting	Fisher Scientific	Novartis	Sino Biological Europe
Biaffin	Fosun Pharma	ONE LOGIC	Sinus Event-Technik
BioCat	Fraunhofer-Institut für Techno- und Wirtschaftsmathematik ITWM	ORIGIO Clinical Monitoring	SOMI Solutions
BioLegend Europe	FreshFields Bruckhaus Deringer	Osborne Clarkeg	Staburo
Biomay	Gowling WLG	Panhans Pharma Consul	Stephenson Harwood

Biotrend Chemikalien	Granzer Regulatory Consulting & Service	Paul Hastings	Stevenato Group
Biozol Diagnostica Vertrieb	Greiner Bio-One	Peak Scientific	SyroCon Consulting
Brand Institute	GlaxoSmithKline (GSK)	Pfizer	TCW
Carl Roth	Heidrick & Struggles	Phaidon International	Tecan Deutschland
Catalent	Hölzel Diagnostika Handels	PharmaCentaur	Tenthpin Management
CG Pharma	Horváth & Partner	PHARM-SOFT Dr. B. Rodu	Thermo Fisher Scientific
Chemgineering	ICON	PHMR	THERON Management Advisors
Choate Hall & Stewart	Informa Pharma Intelligence	Phoenix-Apotheke Mainz	Topmedicare
CMS Legal Services	Instadeep	Pixilicious Enterprises	TriLink BioTechnologies
Cognigy	K-Recruiting	Plan@ IT Services	TriRadial Solutions
Cole-Parmer	Kerafast	Polymun	TRON
Consulimus	Kissel Pharma Consulting	portvier	Trophic Communications
Consultants	Korn Ferry	Powell Gilbert	Universitätsklinikum Frankfurt
Corning	Knauer	Precision Bioservices	UniversitätsKlinikum Heidelberg
Covington	LGC Genomics	Precision for Medicin	VisMederi
CRB Group	Life Technologies (Thermo Fisher Scientific)	Profishop-Bremee	VWR International
Croda International	LKF-Laboratorium für Klinische Forschung	ProfiLab24	Waters
CRS Clinical Research Services Mannheim		Progedo	WE Communications
		Progressive Recruitment	World Courrier
		pure 11	ZSP Patentanwälte
		PriceWaterhouseCoopers (PwC)	

About BioNTech
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.

BioNTech Contacts:

Media Relations
Jasmina Alatovic
+49 6131 9084-0
Media@biontech.de

Investor Relations
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
Investors@biontech.de